文献速递脑血管病神经重症与神经感染

替奈普酶治疗与血栓特征相关的早期再灌注:EXTEND-IA TNK 试验分析

Tenecteplase Treatment and Thrombus Characteristics Associated With Early Reperfusion: An EXTEND-IA TNK Trials Analysis.
PubMed 文献 · Stroke · 2023-02-02

该研究为 EXTEND-IA TNK 试验的汇总分析,纳入大血管闭塞患者,随机接受替奈普酶(0.25 或 0.4 mg/kg)或阿替普酶后行取栓术。总体替奈普酶组早期再灌注率 20%(75/369)高于阿替普酶组 9%(9/96),校正 OR 2.18(95%CI 1.03-4.63)。低血栓负荷亚组中替奈普酶优势明显,而颈内动脉闭塞和高血栓负荷病灶再灌注疗效有限。

要点

  • 替奈普酶组早期再灌注 75/369(20%) vs 阿替普酶组 9/96(9%),校正 OR 2.18(95%CI 1.03-4.63)。
  • 低血栓负荷亚组替奈普酶 66/261(25%) vs 阿替普酶 5/67(7%),校正 OR 3.93(95%CI 1.50-10.33)。
  • 颈内动脉闭塞患者两种溶栓药再灌注疗效均有限,替奈普酶 1/73(1%) vs 阿替普酶 1/19(5%)。

核心结论

  • 在低血栓负荷病灶中,替奈普酶较阿替普酶显示更优的早期再灌注。
  • 颈内动脉闭塞和高血栓负荷病灶的再灌注疗效仍有限。
  • 作者认为需要进一步创新溶栓治疗。

研究设计与样本

  • EXTEND-IA TNK 试验的汇总分析。
  • 大血管闭塞患者随机接受替奈普酶(0.25 或 0.4 mg/kg)或阿替普酶后行取栓术,于澳大利亚和新西兰的医院开展(2015-2019 年)。

主要发现

  • 总体早期再灌注:替奈普酶组 75/369(20%) vs 阿替普酶组 9/96(9%),校正 OR 2.18(95%CI 1.03-4.63)。
  • 低血栓负荷亚组:替奈普酶组 66/261(25%) vs 阿替普酶组 5/67(7%),校正 OR 3.93(95%CI 1.50-10.33)。
  • 高血栓负荷亚组:替奈普酶组 9/108(8%) vs 阿替普酶组 4/29(14%),校正 OR 0.58(95%CI 0.16-2.06);交互作用 P=0.01。
  • 对比剂渗透性:存在渗透性时校正 OR 2.83(95%CI 1.00-8.05),不存在时校正 OR 1.98(95%CI 0.65-6.03);交互作用 P=0.62。
  • 远端 M1 或 M2 闭塞:替奈普酶组 53/176(30%) vs 阿替普酶组 4/42(10%),校正 OR 3.73(95%CI 1.25-11.11);颈内动脉闭塞:替奈普酶组 1/73(1%) vs 阿替普酶组 1/19(5%),校正 OR 0.22(95%CI 0.01-3.83);交互作用 P=0.16。

关键数值与推荐

  • 早期再灌注定义为首次血管造影未见可回收血栓或再灌注>50%。
  • 颅内闭塞部位、对比剂渗透性(残余血流分级)和血栓负荷(血栓负荷评分)通过 CT 血管成像测量。
  • 校正协变量使用混合效应 logistic 回归模型。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者在结论中提出需要进一步创新溶栓治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intracranial occlusion site, contrast permeability, and clot burden are thrombus characteristics that influence alteplase-associated reperfusion. In this study, we assessed the reperfusion efficacy of tenecteplase and alteplase in subgroups based on these characteristics in a pooled analysis of the EXTEND-IA TNK trial (Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke). METHODS: Patients with large vessel occlusion were randomized to treatment with tenecteplase (0.25 or 0.4 mg/kg) or alteplase before thrombectomy in hospitals across Australia and New Zealand (2015-2019). The primary outcome, early reperfusion, was defined as the absence of retrievable thrombus or >50% reperfusion on first-pass angiogram. We compared the effect of tenecteplase versus alteplase overall, and in subgroups, based on the following measured with computed tomography angiography: intracranial occlusion site, contrast permeability (measured via residual flow grades), and clot burden (measured via clot burden scores). We adjusted for covariates using mixed effects logistic regression models. RESULTS: Tenecteplase was associated with higher odds of early reperfusion (75/369 [20%] versus alteplase: 9/96 [9%], adjusted odds ratio [aOR], 2.18 [95% CI, 1.03-4.63]). The difference between thrombolytics was notable in occlusions with low clot burden (tenecteplase: 66/261 [25%] versus alteplase: 5/67 [7%], aOR, 3.93 [95% CI, 1.50-10.33]) when compared to high clot burden lesions (tenecteplase: 9/108 [8%] versus alteplase: 4/29 [14%], aOR, 0.58 [95% CI, 0.16-2.06]; Pinteraction=0.01). We did not observe an association between contrast permeability and tenecteplase treatment effect (permeability present: aOR, 2.83 [95% CI, 1.00-8.05] versus absent: aOR, 1.98 [95% CI, 0.65-6.03]; Pinteraction=0.62). Tenecteplase treatment effect was superior with distal M1 or M2 occlusions (53/176 [30%] versus alteplase: 4/42 [10%], aOR, 3.73 [95% CI, 1.25-11.11]), but both thrombolytics had limited efficacy with internal carotid artery occlusions (tenecteplase 1/73 [1%] versus alteplase 1/19 [5%], aOR, 0.22 [95% CI, 0.01-3.83]; Pinteraction=0.16). CONCLUSIONS: Tenecteplase demonstrates superior early reperfusion versus alteplase in lesions with low clot burden. Reperfusion efficacy remains limited in internal carotid artery occlusions and lesions with high clot burden. Further innovation in thrombolytic therapies are required.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Yogendrakumar V, Churilov L, Guha P, et al. Tenecteplase Treatment and Thrombus Characteristics Associated With Early Reperfusion: An EXTEND-IA TNK Trials Analysis. Stroke. 2023. PMID: 36727510. doi:10.1161/STROKEAHA.122.041061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。